On Monday, RBC Capital updated its outlook for American Healthcare REIT, Inc (NYSE: AHR), raising the stock's price target to $30.00 from the previous $28.00. The firm has maintained its Outperform rating on the shares. The adjustment follows the company's third-quarter financial report for 2024.
The analyst from RBC Capital expressed optimism about AHR's prospects, citing the company's strong positioning to achieve solid organic growth. The positive environment surrounding seniors housing and skilled nursing facilities was highlighted as a favorable backdrop for the company's operations.
In addition to the growth potential, the analyst noted that American Healthcare REIT is now in a better position to make new investments that could drive earnings higher. This improved capacity for accretive investments is a key factor behind the increased earnings estimates and the uplifted price target.
The analyst's commentary emphasized a conservative stance on new investment expectations despite the optimistic outlook. The company's strategic positioning and potential for growth in its sector were underscored as reasons for maintaining the Outperform rating.
RBC Capital's updated price target suggests a confidence in American Healthcare REIT's ability to leverage its position in the market and continue to deliver value to its shareholders. The unchanged Outperform rating alongside the raised price target reflects a positive view on the stock's future performance.
In other recent news, American Healthcare REIT has seen significant developments. The company's third-quarter results and full-year guidance for 2024 surpassed Truist Securities' expectations, leading the firm to increase its price target for the company from $27 to $29. Additionally, American Healthcare REIT recently launched a public offering of 14.5 million shares of common stock with the proceeds set for the acquisition of the remaining 24% minority interest in Trilogy Holdings, LLC, and for the repayment of debt under its credit facilities.
The company has also become the sole owner of Trilogy Holdings through an all-cash deal worth approximately $258 million. KeyBanc Capital Markets and Truist Securities have respectively raised their price targets for American Healthcare REIT to $28 and $27, reflecting the company's recent equity offering and the anticipated exercise of its Trilogy purchase option.
During the company's recent annual meeting, shareholders approved several key proposals, such as the election of directors, ratification of Deloitte & Touche LLP as the independent registered public accounting firm for the fiscal year ending December 31, 2024, and the approval of the American Healthcare REIT, Inc. 2024 Employee Stock Purchase Plan.
Lastly, American Healthcare REIT has provided guidance for a 3.3% increase in 2024 Normalized Funds From Operations (FFO) and a significant rise in same-store net operating income (SSNOI) growth for 2024.
InvestingPro Insights
Recent data from InvestingPro adds depth to RBC Capital's optimistic outlook on American Healthcare REIT (NYSE: AHR). The company's market capitalization stands at $4.24 billion, reflecting its significant presence in the healthcare real estate sector. AHR's revenue growth of 9.88% over the last twelve months and a more impressive 12.76% growth in the most recent quarter align with the analyst's expectations of solid organic growth.
InvestingPro Tips highlight that AHR is trading near its 52-week high, with a strong return of 114.89% over the last year. This performance supports RBC Capital's bullish stance and increased price target. Additionally, analysts predict the company will be profitable this year, which could justify the optimism surrounding its investment potential.
However, investors should note that AHR currently suffers from weak gross profit margins, with a gross profit margin of 16.92% in the last twelve months. This metric may be an area to watch as the company pursues growth and new investments.
For readers seeking a more comprehensive analysis, InvestingPro offers 12 additional tips for AHR, providing a deeper understanding of the company's financial health and market position.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.